STADA Arzneimittel — Q1 2018 Earnings Presentation
10 slides from STADA Arzneimittel's earnings presentation, May 3, 2018
Slide 1: Corporate Presentation Q1/2018 Results
CORPORATE PRESENTATION Q1/2018 Results May 3, 2018
Slide 2: Disclaimer and Notes
DISCLAIMER AND NOTES This STADA Arzneimittel AG (hereinafter "STADA") presentation is intended for information only. It is not intended as or provided in connection with an offer or solicitation for the purchase or sale of any security in any jurisdiction. STADA shall not have any liability arising
Slide 3: Q1/2018 at a Glance
Q1/2018 AT A GLANCE STADA with a good start to the year; increase of adjusted Group sales, driven by both segments Strong increase in EBITDA, with considerable margin improvement in both Generics and Branded Business Good start to the year Transformation programme has already yielded positive result
Slide 4: Financial Overview
FINANCIAL OVERVIEW Group results €m Q1/2018 Q1/2017 Δ Sales 558.1 566.3 -1% Sales (adj.)1 573.4 552.0 +4% EBITDA 118.6 108.6 +9% EBITDA (adj.)2 118.4 108.5 +9% Financial result -7.8 -9.6 -19% Income taxes 22.4 15.2 +48% Net Income 56.7 49.2 +15% Net Income (adj.)2 60.9 53.3 +14% 1) Adjusted for curr
Slide 5: Generics: Significant Increase in Profitability
GENERICS SIGNIFICANT INCREASE IN PROFITABILITY Segment results €m Q1/2018 Q1/2017 Δ Sales 326.8 325.9 0% Sales (adj.)1 332.8 319.0 +4% EBITDA (adj.)2 82.3 69.4 +19% EBITDA margin (adj.)2 25.2% 21.3% +390bps 1) Adjusted for currency and portfolio effects. 2) Adjusted for special items. STADA Corporat
Slide 6: Branded Products: Significant Increase in Profitability
BRANDED PRODUCTS SIGNIFICANT INCREASE IN PROFITABILITY Segment results €m Q1/2018 Q1/2017 Δ Sales 231.3 240.4 -4% Sales (adj.)1 240.6 233.0 +3% EBITDA (adj.)2 63.1 57.0 +11% EBITDA margin (adj.)2 27.3% 23.7% +360bps 1) Adjusted for currency and portfolio effects. 2) Adjusted for special items. STADA
Slide 7: Positive Cash Flow Development
POSITIVE CASH FLOW DEVELOPMENT €m1 Q1/2018 Q1/2017 Δ Operating cash flow 80.6 59.5 +35% R&D/Intangibles -18.2 -22.5 -19% Capex/Other -10.5 -9.6 +10% Acquisitions 0.0 -1.6 >100% Free cash flow (before dividends) 51.9 25.8 >100% Net working capital at €649m (December 31, 2017: €679m) 1) As a result of
Slide 8: Appendix
APPENDIX STADA Corporate Presentation • May 3, 2018 Page 8
Slide 9: Reconciliation Q1/2018
RECONCILIATION Q1/2018 in €m1 Q1/2018 Impairments/ Effects from Q1/2018 reported write-ups on purchase price adjusted non-current assets allocations and product acquisitions2 EBITDA 118.6 - -0.2 118.4 Balance from depreciation/amortization 30.4 -1.8 -3.3 25.3 and impairments/write-ups on intangible
Slide 10: Financial Calendar & Contact
FINANCIAL CALENDAR & CONTACT Financial calendar 2018 June 6, 2018 Annual Meeting 2018 August 9, 2018 Publication half-year and second quarter 2018 results Please note that these dates could be subject to change. Contact Leslie Isabelle Iltgen Vice President Investor Relations Telephone: +49 (0) 6101